Lakefront Biotherapeutics (GLPGF) Change in Accured Expenses (2018 - 2025)
Lakefront Biotherapeutics' (GLPGF) quarterly Change in Accured Expenses came in at -$163042.1 in Q1 2025, down 100.62% quarter-over-quarter from -$81268.2 in Q3 2024.
Powered by 
Analysis
Lakefront Biotherapeutics (GLPGF) Change in Accured Expenses (2018 - 2025) Analysis & Trends
Lakefront Biotherapeutics (GLPGF) has reported Change in Accured Expenses for 4 consecutive years, with -$163042.1 the latest figure, recorded in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.50 Bn | 197.51 Bn | 7.24 Bn | 852.00 Mn |
| 2 | Gilead Sciences | 181.29 Bn | 178.11 Bn | 6.22 Bn | 338.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 222.50 Mn |
| 4 | Regeneron Pharmaceuticals | 82.55 Bn | 74.56 Bn | 3.93 Bn | 492.70 Mn |
| 5 | Argenx Se | 61.65 Bn | 56.47 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.65 Bn | 49.52 Bn | 52.00 Mn | 11.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.18 Bn | 30.87 Bn | 992.69 Mn | 61.62 Mn |
| 8 | Biogen | 31.36 Bn | 30.07 Bn | 1.96 Bn | -49.70 Mn |
| 9 | Roivant Sciences | 30.01 Bn | 30.01 Bn | 1.16 Mn | -13.91 Mn |
| 10 | Lakefront Biotherapeutics | 1.73 Bn | 1.73 Bn | 3.51 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2025 | -163,042.09 |
| Sep 30, 2024 | -81,268.24 |
| Sep 30, 2019 | -2.15 Mn |
| Jun 30, 2019 | -2.62 Mn |
| Mar 31, 2019 | -1.37 Mn |
| Sep 30, 2018 | -943,297.76 |
| Jun 30, 2018 | -455,895.77 |
| Mar 31, 2018 | -417,701.15 |